[theold]

The Associated Press reported that AstraZeneca’s quarterly update for the third quarter indicated that the pharmaceutical company “is expected to gradually shift to a small profit” pricing model while receiving new orders for vaccines; The "limited" profit in the fourth quarter will cover the cost of developing COVID-19 antibody cocktail therapy.


AstraZeneca has reached an agreement with Oxford University, which co-developed the vaccine, and the AZ vaccines provided so far are sold at a "cost price" of approximately US$2 to US$3. Other vaccine manufacturers such as Pfizer and Moderna continue to generate huge profits.


https://www.ettoday.net/news/20211114/2123335.htm